LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是看看是否添加一种药物称为CellCept（也称为霉酚酸酯）， 格列卫（也称为甲磺酸伊马替尼或ST 1571）治疗慢性粒细胞白血病（CML）患者将使一种名为BCR-ABL的异常蛋白质的水平降低到比格列卫本身更大的程度。 这项研究还将试图看看这样做是否会使患者在缓解或进展到更晚期和更危险的CML阶段时不太可能出现白血病复发等问题。 最后，该研究将检查另一种名为林恩激酶的蛋白质是否异常高，以及伊马替尼和麦考酚酯联合使用是否会降低其水平。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to see if adding a medicine called CellCept (also called mycophenolate mofetil) to Gleevec (also called imatinib mesylate or ST1571) for patients with chronic myelogenous leukemia (CML) will make levels of an abnormal protein named BCR-ABL decrease to a greater extent than would happen with Gleevec by itself. The study will also try to see if doing so makes patients less likely to have problems from their leukemia like relapses if in remission or progression to more advanced and dangerous phases of CML. Finally, the study will examine whether another protein called LYN kinase is abnormally high and whether its levels go down with the combination of imatinib and mycophenolate.